Chiltern, Charles River Labs Partner on Early-phase Studies
Friday, February 26, 2010
The two companies will collaborate on studies using radiolabelled investigational products out of the CROs’ Europe-based facilities.
Chiltern’s early stage division—Chiltern Early Phase—in Dundee, Scotland, will perform the clinical aspects of the studies. The CRO has a 42-bed clinical pharmacology unit located in a UK National Health Service hospital and medical school. Charles River’s Metabolism and Pharmacokinetics facilty in Edinburgh includes a GMP clean room, licensed for the manufacture of radiolabelled drug products. The close proximity of the two laboratories enables the companies to turn around radioactivity data within 24 hours.
“This new partnership is an exciting collaboration. Charles River’s reputation is world-renowned for their conduct of studies using radiolabelled investigational products. Their extensive experience includes submission and review procedures for radiolabelled studies in man, including dosimetry calculations and submission to ARSAC,” said Chiltern CEO Glenn Kerkhof in a statement. “These complementary strengths add a new dimension to the full CRO services that Chiltern already provides, continuing to demonstrate our commitment to providing our clients with the highest standard of quality and expertise.”